Closed, phosphorylcholine-coated circuit and reduction of systemic heparinization for cardiopulmonary bypass: The intraoperative ECMO concept

International Journal of Artificial Organs

Volumn 25, Issue 9, 2002, Pages 875-881

  Ranucci, Marco ^a   Pazzaglia, A ^a   Isgro G ^a   Cazzaniga, A ^a   Ditta, A ^a   Boncilli, A ^a   Cotza, M ^a   Carboni, G ^a   Brozzi, S ^a   Bonifazi, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Biocompatible materials; Cardiopulmonary bypass; Heparin

Indexed keywords

BIOCOMPATIBILITY; COATED MATERIALS; PATIENT MONITORING; PATIENT TREATMENT; POLYSACCHARIDES;

% REDUCTIONS; ACTIVATED CLOTTING TIME; BLEEDINGS; CARDIOPULMONARY BYPASS; CLINICAL OUTCOME; HEPARINIZATION; INTRA-OPERATIVE; PHOSPHORYLCHOLINE; REVASCULARIZATION; THROMBUS FORMATION;

TIMING CIRCUITS;

ACETYLSALICYLIC ACID; DICOUMAROL DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PHOSPHORYLCHOLINE; TICLOPIDINE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BIOCOMPATIBILITY; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL PROTOCOL; CONTROLLED STUDY; EXTRACORPOREAL OXYGENATION; FEMALE; HEART DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PEROPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE THROMBOSIS; SAFETY; THROMBOCYTE COUNT; THROMBOCYTE PRESERVATION; THROMBOGENESIS; THROMBUS; TIME; TREATMENT OUTCOME;

EID: 0036770386     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880202500910     Document Type: Article

References (20)

1. Videm V, Svennevig JL, Fosse F, et al. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992; 103: 806-13.
2. Gu YJ, Van Oeveren W, Akkerman C, et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 917-22.
3. Fosse F, Moen O, Johnson F, et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994; 58: 472-7.
4. Ranucci M, Cirri S, Conti D, et al. Beneficial effects of Duraflo II heparin-coated circuits on postperfusion lung dysfunction. Ann Thorac Surg 1996; 61: 76-81.
5. Heyer EJ, Lee KS, Manspeizer HE, et al. Heparin-bonded cardiopulmonary bypass circuits reduce cognitive dysfunction. J Cardiothorac Vasc Anesth 2002; 16: 37-42.
6. Ranucci M, Mazzucco A, Pessotto R, et al. Heparin-coated circuits for high-risk patients: A multicenter, prospective, randomized trial. Ann Thorac Surg 1999; 67: 994-1000.
7. Øvrum F, Fosse F, Moilnes TE, et al. Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation. Eur J Cardiothorac Surg 1996; 10: 54-60.
8. Øvrum F, Am Holen F, Tangen G, et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects. Ann Thorac Surg 1995; 60: 365-71.
9. Aldea GS, Doursounian M, O'Gara P, et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: A prospective, randomized study. Ann Thorac Surg 1996; 62: 410-8.
10. Aldea GS, O'Gara P, Shapira OM, et al. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. Ann Thorac Surg 1998; 65: 425-33.
11. Ranucci M, Cazzaniga A, Soro G, Isgro G, Frigiola A, Menicanti L. Antithrombin III saving effect of reduced systemic heparinization and heparin-coated circuits. J Cardiothorac Vasc Anesth 2002; 16: 316-20.
12. Yu J, Lamba NMK, Courtney JM, et al. Polymeric biomaterials: Influence of phosphorylcholine polar groups on protein adsorption and complement activation. Int J Artif Organs 1994; 17: 499-504.
13. Von Segesser LK, Tönz M, Leskosek B, Turina M. Evaluation of phospholipidic surface coatings ex vivo. Int J Artif Organs 1994; 17: 294-300.
14. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: Correlation with subclinical plasma coagulation. Ann Thorac Surg 1995; 58: 799-805.
15. De Somer F, Van Belleghem Y, Foubert L, et al. In vivo evaluation of a phosphorylcholine coated cardiopulmonary bypass circuit. J Extra Corpor Technol 1999; 31: 62-6.
16. De Somer F, Francois K, Van Oeveren W, et al. Phosphorycholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. Eur J Cardiothorac Surg 2000; 18: 602-6.
17. Kaplon RJ, Smedira NG. Extracorporeal membrane oxygenation in adults. In; Goldstein DJ, Oz MC, eds. Cardiac Assist Devices. Armonk, NY: Futura Publishing, 2000; pp. 263-73.
18. Horbett TA. Protein adsorption on biomaterials. In: Cooper SL, Peppas NA, eds. Biomaterials: Interfacial Phenomena and Applications. Washington, DC: American Chemical Society, 1982; pp. 233-44.
19. Walton AG, Koltisko B. Protein structure and the kinetics of interaction with surfaces. In: Cooper SL, Peppas NA, eds. Biomaterials: Interfacial Phenomena and Applications. Washington, DC: American Chemical Society, 1982; pp. 245-64.
20. Ranucci M, Cazzaniga A,, Isgrò G, et al. Gabexate mesilate and antithrombin III for intraoperative anticoagulation in heparin pretreated patients. Perfusion 1999; 14: 357-62.